Literature DB >> 20811157

Stemming vision loss with stem cells.

Valentina Marchetti1, Tim U Krohne, David F Friedlander, Martin Friedlander.   

Abstract

Dramatic advances in the field of stem cell research have raised the possibility of using these cells to treat a variety of diseases. The eye is an excellent target organ for such cell-based therapeutics due to its ready accessibility, the prevalence of vasculo- and neurodegenerative diseases affecting vision, and the availability of animal models to demonstrate proof of concept. In fact, stem cell therapies have already been applied to the treatment of disease affecting the ocular surface, leading to preservation of vision. Diseases in the back of the eye, such as macular degeneration, diabetic retinopathy, and inherited retinal degenerations, present greater challenges, but rapidly emerging stem cell technologies hold the promise of autologous grafts to stabilize vision loss through cellular replacement or paracrine rescue effects.

Entities:  

Mesh:

Year:  2010        PMID: 20811157      PMCID: PMC2929728          DOI: 10.1172/JCI42951

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  122 in total

Review 1.  Stem cells and their niches.

Authors:  Kateri A Moore; Ihor R Lemischka
Journal:  Science       Date:  2006-03-31       Impact factor: 47.728

Review 2.  Age-related macular degeneration.

Authors:  Paulus T V M de Jong
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

3.  Failure of transdifferentiation of adult hematopoietic stem cells into neurons.

Authors:  Laurent Roybon; Zhi Ma; Fredrik Asztely; Anna Fosum; Sten Eirik W Jacobsen; Patrik Brundin; Jia-Yi Li
Journal:  Stem Cells       Date:  2006-03-23       Impact factor: 6.277

4.  Potential role of microglia in retinal blood vessel formation.

Authors:  Daniella Checchin; Florian Sennlaub; Etienne Levavasseur; Martin Leduc; Sylvain Chemtob
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-08       Impact factor: 4.799

5.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

6.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

7.  Human embryonic stem cell-derived cells rescue visual function in dystrophic RCS rats.

Authors:  Raymond D Lund; Shaomei Wang; Irina Klimanskaya; Toby Holmes; Rebeca Ramos-Kelsey; Bin Lu; Sergej Girman; N Bischoff; Yves Sauvé; Robert Lanza
Journal:  Cloning Stem Cells       Date:  2006

8.  Characterization of free-floating spheres from human trabecular meshwork (HTM) cell culture in vitro.

Authors:  P Gonzalez; D L Epstein; C Luna; P B Liton
Journal:  Exp Eye Res       Date:  2005-11-28       Impact factor: 3.467

9.  Genome-wide expression profile of human trabecular meshwork cultured cells, nonglaucomatous and primary open angle glaucoma tissue.

Authors:  Paloma B Liton; Coralia Luna; Pratap Challa; David L Epstein; Pedro Gonzalez
Journal:  Mol Vis       Date:  2006-07-12       Impact factor: 2.367

10.  Retinal repair by transplantation of photoreceptor precursors.

Authors:  R E MacLaren; R A Pearson; A MacNeil; R H Douglas; T E Salt; M Akimoto; A Swaroop; J C Sowden; R R Ali
Journal:  Nature       Date:  2006-11-09       Impact factor: 49.962

View more
  15 in total

1.  In Vitro and In Vivo Proteomic Comparison of Human Neural Progenitor Cell-Induced Photoreceptor Survival.

Authors:  Melissa K Jones; Bin Lu; Dawn Zhaohui Chen; Weston R Spivia; Augustus T Mercado; Alexander V Ljubimov; Clive N Svendsen; Jennifer E Van Eyk; Shaomei Wang
Journal:  Proteomics       Date:  2019-01-02       Impact factor: 3.984

2.  An eye for discovery.

Authors:  Andreas Stahl; Lois E H Smith
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

Review 3.  Stem cells for retinal replacement therapy.

Authors:  Jeffrey H Stern; Sally Temple
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

4.  Induction of trabecular meshwork cells from induced pluripotent stem cells.

Authors:  Qiong J Ding; Wei Zhu; Amy C Cook; Kristin R Anfinson; Budd A Tucker; Markus H Kuehn
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-10-08       Impact factor: 4.799

Review 5.  Recent perspectives on the delivery of biologics to back of the eye.

Authors:  Mary Joseph; Hoang M Trinh; Kishore Cholkar; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Deliv       Date:  2016-09-06       Impact factor: 6.648

6.  Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow derived stem cells in the treatment of Dominant Optic Atrophy.

Authors:  Jeffrey N Weiss; Steven Levy
Journal:  Stem Cell Investig       Date:  2019-12-05

Review 7.  Ophthalmic transplantology: posterior segment of the eye--part II.

Authors:  Małgorzata Nita; Barbara Strzałka-Mrozik; Andrzej Grzybowski; Wanda Romaniuk; Urszula Mazurek
Journal:  Med Sci Monit       Date:  2012-06

Review 8.  Loss of daylight vision in retinal degeneration: are oxidative stress and metabolic dysregulation to blame?

Authors:  Claudio Punzo; Wenjun Xiong; Constance L Cepko
Journal:  J Biol Chem       Date:  2011-11-10       Impact factor: 5.157

Review 9.  Progenitors for the corneal endothelium and trabecular meshwork: a potential source for personalized stem cell therapy in corneal endothelial diseases and glaucoma.

Authors:  Wing Yan Yu; Carl Sheridan; Ian Grierson; Sharon Mason; Victoria Kearns; Amy Cheuk Yin Lo; David Wong
Journal:  J Biomed Biotechnol       Date:  2011-12-06

10.  Stem cells: a new paradigm for disease modeling and developing therapies for age-related macular degeneration.

Authors:  Heather Melville; Matthew Carpiniello; Kia Hollis; Andrew Staffaroni; Nady Golestaneh
Journal:  J Transl Med       Date:  2013-03-01       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.